Project Grant R21AI196880
Award Date 8/6/26
Completion Date 7/31/28
Dollars Obligated $245K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $225,628 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify genetic mechanisms of polyene resistance in Candida glabrata using saturating transposon mutagenesis coupled with next-generation DNA sequencing (TN-SEQ). The project will implement TN-SEQ to mutate and barcode every gene in C. glabrata and profile resistance to three approved...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $412,324 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate whether echinocandin susceptibility can be restored to cross-resistant Candida strains by targeting genes that antagonize FKS gene products. The research uses genome-wide transposon sequencing screens in two cross-resistant derivatives of Candida glabrata to identify candidate genes and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $437,250 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize genetic and phenotypic diversity of Candida parapsilosis populations in bloodstream infections and to identify genetic variants and genes associated with echinocandin heteroresistance or tolerance. C. parapsilosis is the second or third most common cause of candidemia and a...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant K99AI201933) to define the fungal and host determinants of Candida auris skin colonization. The research addresses mechanisms by which Candida auris, an emerging multidrug-resistant fungal pathogen classified by the...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Davis $191,916 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support project grant K08AI199044, a genetics approach to Candida albicans gastrointestinal colonization resistance. The research addresses invasive candidiasis, which occurs when C. albicans enters the bloodstream and disseminates throughout the body with mortality approaching 50 percent....
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $230,313 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a genome-wide CRISPR screening platform in diploid Candida albicans for identifying mechanisms of antifungal resistance. The project will create tools for efficient DNA transformation and CRISPR-based genome editing in C. albicans, then apply these tools to perform genome-wide screening to...
- The National Institute of Allergy and Infectious Diseases awarded Texas A&M University System Health Science Center $192,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into novel antifungal therapeutics. The award funds structure-based design, synthesis, and validation of small molecule inhibitors targeting fungal SEC14 phosphatidylinositol transfer proteins as a strategy to combat multi-drug-resistant fungal infections,...
- The National Institute of Allergy and Infectious Diseases awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $449,625 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study regulation of Candida albicans biofilm formation on central venous catheters. The project investigates how transcription factor networks control Candida albicans biofilm development under physiological bloodstream conditions. Candida albicans...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $437,250 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Candida glabrata population diversity during gastrointestinal tract colonization and intra-abdominal candidiasis. The research addresses the inadequate understanding of intra-abdominal candidiasis pathogenesis and challenges the established paradigm that sterile site infections stem...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $713,383 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms and dynamics of genome plasticity in antifungal-resistant Candida species. The project addresses the molecular drivers of antifungal resistance in Candida albicans, Candida glabrata, and Candida auris through examination of large DNA amplification events, aneuploid...